Financial Performance - The company's operating revenue for the third quarter was ¥7,290,453,129.77, an increase of 0.26% year-on-year[5] - Net profit attributable to shareholders was ¥14,900,818.83, representing a significant increase of 114.18% compared to the same period last year[5] - The company reported a decrease in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to -¥2,181,601.45, a decline of 98.49%[5] - Total operating revenue for the current period was ¥21,245,520,041.34, a decrease of 5.55% from ¥22,493,111,043.98 in the previous period[31] - Net profit for the current period was a loss of ¥253,138,793.74, an improvement from a loss of ¥426,192,132.86 in the previous period[32] - The total comprehensive income for the current period was a loss of ¥260,267,288.50, compared to a loss of ¥440,189,463.49 in the previous period[33] - Basic and diluted earnings per share were both -0.0696, an improvement from -0.1351 in the previous period[33] Cash Flow - The net cash flow from operating activities decreased by 67.15% to ¥1,393,589,180.45 due to a reduction in cash received from operating activities[18] - Cash inflow from operating activities totaled ¥27,192,853,928.79, down from ¥31,832,380,207.62 in the previous period[35] - The net cash flow from operating activities was 1,393,589,180.45, a decrease of 67.2% compared to 4,242,725,760.60 from the previous period[36] - Cash outflows from operating activities totaled 25,799,264,748.34, down from 27,589,654,447.02, indicating a reduction of 6.5%[36] - The net cash flow from investing activities was -2,359,594,268.00, slightly improved from -2,440,506,826.18 in the prior period[36] - Cash inflows from financing activities amounted to 14,013,443,723.22, an increase of 19.3% compared to 11,735,819,003.85[37] - The net cash flow from financing activities was 1,776,309,881.16, a significant recovery from -338,320,617.81 in the previous period[37] - The ending balance of cash and cash equivalents was 2,794,082,282.08, down from 3,574,408,444.35, reflecting a decrease of 21.8%[37] - The company paid 9,085,808,853.42 in debt repayments, which increased from 7,038,487,997.63, representing a rise of 29.1%[37] - The total cash outflows related to financing activities were 12,237,133,842.06, slightly up from 12,074,139,621.66, indicating a 1.4% increase[37] - The company received 10,866,615,440.40 in cash from borrowings, which is a slight increase from 10,679,414,047.74, showing a growth of 1.8%[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥78,309,580,150.14, reflecting a 1.67% increase from the previous year[6] - The total assets as of September 30, 2025, amounted to CNY 78.31 billion, an increase from CNY 77.02 billion at the beginning of the period[26] - Current assets reached CNY 15.91 billion, up from CNY 13.12 billion at the start of the period, indicating a growth of approximately 21.2%[27] - The company's cash and cash equivalents increased to CNY 6.83 billion from CNY 4.77 billion, representing a growth of about 43%[26] - Short-term borrowings slightly increased to CNY 5.37 billion from CNY 5.34 billion, showing a marginal rise[28] - Non-current liabilities rose to CNY 19.13 billion from CNY 15.93 billion, reflecting an increase of approximately 20.5%[28] - The total liabilities as of September 30, 2025, were CNY 50.68 billion, compared to CNY 48.98 billion at the beginning of the period, indicating an increase of about 3.5%[28] - Total equity attributable to shareholders of the parent company was ¥21,585,169,660.71, a decrease from ¥21,783,601,095.48 in the previous period[28] Operational Highlights - The company experienced a 36.83% increase in receivables financing, totaling ¥1,056,277,872.65, attributed to an increase in bank acceptance bills[13] - The company’s prepayments increased by 55.21% to ¥891,794,031.34, driven by an increase in advance payments for pulp[13] - The company recorded a 139.82% increase in income tax expenses, amounting to ¥130,152,784.95, due to higher profit levels and an expanded consolidation scope[16] - In Q3 2025, the company produced 1.8758 million tons of PVC resin, 1.3074 million tons of caustic soda, 407,400 tons of viscose fiber, and 228,700 tons of viscose yarn[23] - The company emphasized a market-oriented approach, focusing on differentiated downstream products to enhance market competitiveness[23] - The company aims to strengthen innovation and market collaboration to improve production efficiency and meet market demands[23] Audit and Compliance - The company did not undergo an audit for the third quarter financial report[38]

Financial Performance - The company's revenue for Q3 2025 was ¥1,042,166,389.29, representing a 9.19% increase compared to the same period last year[3] - The net profit attributable to shareholders was -¥27,165,209.53, a decrease of 80.92% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,276,537.39, a decrease of 74.17% compared to the previous year[3] - For the first three quarters of 2025, the company achieved operating revenue of RMB 267,363.87 million, a year-on-year decrease of 5.39%[15] - The net profit attributable to shareholders for the same period was RMB -2,138.70 million, an increase of 82.78% year-on-year[15] - In Q3 2025, the company reported operating revenue of RMB 104,216.64 million, a year-on-year growth of 9.19%[15] - Total revenue for the current period is ¥2,673,638,742.11, a decrease of 5.37% from ¥2,825,935,926.99 in the previous period[30] - The net profit for the current period is -26,230,892.14, compared to -124,180,426.78 in the previous period, showing a significant improvement[31] - Operating profit for the current period is -35,804,257.97, an improvement from -119,699,288.76 in the previous period[31] - Total comprehensive income for the current period is -63,301,430.15, compared to -154,305,996.91 in the previous period, reflecting a reduction in losses[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,301,377,285.05, down 1.92% from the end of the previous year[3] - Total current assets decreased to ¥6,530,214,262.62 from ¥6,875,791,256.55, reflecting a decline of 5.02%[28] - Total non-current assets increased to ¥5,771,163,022.43 from ¥5,666,495,138.08, showing a growth of 1.85%[28] - Total liabilities decreased to ¥2,929,583,566.20 from ¥3,270,676,576.56, a reduction of 10.43%[28] - The company's total equity increased to ¥9,371,793,718.85 from ¥9,271,609,818.07, reflecting a growth of 1.08%[29] Cash Flow - The company's cash flow from operating activities was -¥436,673,090.75, a decrease of 205.77% compared to the same period last year[3] - Cash flow from operating activities shows a net outflow of -436,673,090.75, compared to -142,812,352.08 in the previous period, indicating a worsening cash flow situation[32] - The company received cash from investment activities totaling 4,754,090,112.22, compared to 7,661,136,503.58 in the previous period, indicating a decrease in investment inflows[32] - The net cash flow from financing activities is 180,044,633.76, a recovery from -316,812,088.02 in the previous period[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 67,903[10] - As of the report date, the controlling shareholder, BGI Holdings, pledged 10.375 million shares, accounting for 79.18% of its holdings and 24.80% of the total share capital[20] - The shareholder, Shenzhen Shenghua Investment, reduced its holdings by 1.2507 million shares, representing 0.2990% of the total share capital, as part of a planned reduction of up to 6.2748 million shares[23] - BGI Holdings transferred 16.7327 million shares at a price of 44.10 yuan per share, totaling approximately 738 million yuan, reducing its stake from 38.17% to 31.32%[24] Business Segments - The reproductive health business generated operating revenue of RMB 643 million, down 28.4% compared to RMB 899 million in the same period of 2024[17] - The non-invasive prenatal genetic testing business saw a revenue decline of approximately 36% year-on-year[17] - Revenue from the hereditary disease clinical diagnosis series in the tertiary prevention business grew by approximately 17% year-on-year[17] - The oncology and chronic disease prevention business achieved revenue of 358 million yuan, a decrease of 8.8% compared to 393 million yuan in the same period of 2024[18] - The infection prevention business reported revenue of 75 million yuan, a year-on-year increase of 41.7% from 53 million yuan in 2024, driven by the development of a pathogen sequencing platform and automation systems[18] - The multi-omics and synthesis business generated revenue of 452 million yuan, remaining stable compared to the previous year, with single-cell sequencing revenue growing approximately 93%[18] - The precision medicine testing comprehensive solution business achieved revenue of 1.124 billion yuan, an increase of 11.2% from 1.010 billion yuan in 2024, due to accelerated local clinical application and successful overseas market expansion[19] Expenses - The sales expenses decreased by 17.73%, management expenses decreased by 17.76%, and R&D expenses decreased by 16.38% during the reporting period[15] - Research and development expenses decreased to ¥332,812,703.86, a reduction of 16.43% compared to ¥398,014,771.10 in the previous period[30] Other Financial Metrics - The basic earnings per share were -¥0.0653, an increase of 81.08% year-on-year[3] - The weighted average return on equity was -0.29%, an increase of 1.14% compared to the previous year[3] - The company recorded an increase of RMB 82.11 million in credit impairment losses compared to the same period last year due to extended customer payment cycles[16] - The company incurred a tax expense of -19,791,439.13, compared to -2,842,029.91 in the previous period, indicating a higher tax burden despite losses[31]

Financial Performance - The company's revenue for Q3 2025 reached ¥550,232,956.42, representing a year-on-year increase of 14.37%[5] - Net profit attributable to shareholders was ¥23,895,172.82, up 35.60% compared to the same period last year[5] - The company's revenue for the first three quarters of 2025 reached CNY 154,001.08 million, representing a year-on-year increase of 15.07%[14] - Net profit for the same period was CNY 6,322.35 million, up 9.80% year-on-year, while net profit excluding non-recurring gains and losses increased by 34.95% to CNY 6,036.55 million[14] - Total operating revenue for the current period reached ¥1,540,010,808.25, an increase of 15.8% compared to ¥1,338,355,655.40 in the previous period[18] - Net profit for the current period was ¥63,317,805.55, compared to ¥57,578,246.30 in the previous period, representing an increase of 9.5%[19] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥83,403,268.44, a significant increase of 522.91%[10] - The company's cash and cash equivalents at the end of the reporting period amounted to CNY 690,207,700.33, up from CNY 455,951,258.35 at the beginning of the period[15] - Operating cash inflow for the current period reached ¥1,697,072,346.89, an increase of 15.6% compared to ¥1,468,209,555.65 in the previous period[21] - Net cash flow from operating activities was ¥83,403,268.44, a significant recovery from a net outflow of ¥19,721,427.74 in the previous period[22] - The ending balance of cash and cash equivalents decreased to ¥346,887,775.95 from ¥721,115,565.35, indicating a cash reduction of 51.9%[22] - The company received cash from investment recovery amounting to ¥1,205,055,302.68, marking a significant inflow from investments[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,638,035,525.88, reflecting a growth of 22.26% from the previous year[5] - The company's total assets increased to ¥2,638,035,525.88 from ¥2,157,668,309.03, marking a growth of 22.3%[17] - Total liabilities rose to ¥1,112,154,019.46, up from ¥696,592,211.05, indicating a year-over-year increase of 59.6%[17] - The company’s total liabilities increased significantly, with accounts payable rising by 155.39% to ¥696,456,665.65[9] - Deferred income tax liabilities increased to ¥49,634,465.75 from ¥41,205,986.45, a rise of 20.0%[17] Shareholder Information - The top shareholder, Chen Peijun, holds 35.50% of the shares, while the second-largest shareholder holds 14.50%[12] - The company has a total of 17,875 common shareholders at the end of the reporting period[12] Operational Efficiency - The increase in revenue was primarily driven by a sales volume growth exceeding 15% and a recovery in product gross margin despite global economic fluctuations and intensified market competition[14] - The company reported a significant reduction in management expenses compared to the previous year, which had higher costs related to its IPO activities[14] - Other income and non-operating income were notably lower this year, with no significant government subsidies received compared to CNY 15.7 million in the previous year[14] - The company's financial expenses increased by 110.08% due to reduced exchange gains[10] - The company’s investment income showed a significant loss of ¥11,845,788.01, primarily due to the depreciation of the Euro[10] Earnings Per Share - The company reported a basic earnings per share of ¥0.1195, which is a 35.64% increase year-on-year[5] - Basic earnings per share for the current period was ¥0.3161, compared to ¥0.2961 in the previous period, showing an increase of 6.7%[20]

Financial Performance - The company's operating revenue for the third quarter was ¥67,337,262.23, representing a year-on-year increase of 6.77%[4] - The total profit for the quarter was ¥16,677,278.11, a decrease of 32.02% compared to the same period last year[4] - The net profit attributable to shareholders was ¥16,724,595.21, down 24.77% year-on-year[4] - The basic earnings per share for the quarter was ¥0.13, a decrease of 37.36% year-on-year[5] - Total revenue for the first three quarters of 2025 was CNY 183,254,013.38, a decrease of 2.3% compared to CNY 186,963,269.46 in the same period of 2024[20] - Net profit for the first three quarters of 2025 was CNY 51,789,024.41, down 27.6% from CNY 71,568,858.96 in the previous year[21] - Earnings per share (EPS) for the first three quarters of 2025 was CNY 0.39, compared to CNY 0.69 in the same period of 2024[22] Research and Development - Research and development expenses totaled ¥8,473,218.90, accounting for 12.58% of operating revenue, an increase of 2.28 percentage points from the previous year[5] - The company plans to increase investment in the development of third-generation semiconductor mask plates, contributing to higher R&D expenses[10] - Research and development expenses rose to CNY 20,266,839.36, an increase of 17.5% from CNY 17,194,999.97 year-over-year[20] Assets and Liabilities - The company's total assets increased by 6.58% to ¥1,399,579,094.94 compared to the end of the previous year[5] - Total assets increased to CNY 1,399,579,094.94, up from CNY 1,313,154,265.85 in the previous year[18] - Total liabilities rose to CNY 193,306,740.33, compared to CNY 109,288,840.79 in the same period last year[17] - Non-current assets totaled CNY 977,786,048.53, an increase from CNY 771,770,017.26 year-over-year[18] - Current liabilities decreased slightly to CNY 92,829,736.25 from CNY 96,084,858.18 in the previous year[17] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 38.94% due to a decline in revenue and an increase in accounts receivable[10] - In the first three quarters of 2025, the net cash flow from operating activities was ¥43,413,929.40, a decrease of 38.93% compared to ¥71,101,977.22 in the same period of 2024[24] - Total cash inflow from investment activities was ¥410,654,160.03, significantly higher than ¥120,164,505.56 in the previous year, indicating a strong increase in investment recovery[24] - The net cash flow from investment activities was -¥96,505,085.65, an improvement from -¥591,499,324.58 in the same period last year, reflecting better investment management[24] - Cash inflow from financing activities totaled ¥113,292,263.26, down from ¥648,802,852.72 in the previous year, indicating a reduction in financing activities[24] - The net cash flow from financing activities was ¥54,699,330.94, a significant decrease compared to ¥559,428,479.05 in the same period of 2024[24] - The ending balance of cash and cash equivalents was ¥53,216,219.97, down from ¥247,806,696.65 at the end of the previous year[24] - Total cash outflow from operating activities was ¥118,716,002.72, an increase of 6.67% compared to ¥111,801,034.73 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,753[12] - The top three shareholders hold a combined 54.17% of shares: Ke Hanqi (19.75%), Ye Xiaolong (19.75%), and Zhang Daogu (14.67%)[12] - The company has a total of 4,882,500 shares held by Shenzhen Tongchuang Jinxiu Asset Management Co., accounting for 3.66% of total shares[12] - The company has not disclosed any significant changes in shareholder participation in margin trading or stock lending activities[14] - There are no known related party transactions among the top shareholders, except for Ke Hanqi, Ye Xiaolong, and Zhang Daogu, who are identified as acting in concert[13] Operational Insights - The company experienced a 30.67% decrease in total profit for the year-to-date period, primarily due to strategic price reductions for certain customers[9] - The weighted average return on equity was 1.40%, a decrease of 6.66 percentage points compared to the previous year[5] - The company did not report any new product launches or technological developments during this period[25] - The company has not reported any significant new strategies or product developments during the reporting period[14]

Financial Performance - The company's operating revenue for the current period is CNY 1,688,388,279.42, a decrease of 49.86% compared to the same period last year[5] - The total profit for the current period is CNY 72,751,518.26, an increase of 166.08% year-on-year[5] - The net profit attributable to shareholders for the current period is CNY 53,177,929.61, reflecting a 164.75% increase compared to the same period last year[5] - The basic earnings per share for the current period is CNY 0.0284, up 164.75% year-on-year[6] - The weighted average return on equity is 1.26%, an increase of 2.91 percentage points compared to the previous year[6] - The net loss for the first three quarters of 2025 was CNY 547,661,811.81, compared to a net loss of CNY 1,344,654,423.78 in the same period of 2024[22] - The operating profit for the first three quarters of 2025 was CNY -638,510,743.68, an improvement from CNY -1,604,861,415.84 in 2024[22] - The basic earnings per share for the first three quarters of 2025 was CNY -0.2901, compared to CNY -0.7160 in the same period of 2024[22] Revenue and Costs - The company experienced a 41.27% decrease in operating revenue year-to-date, primarily due to reduced sales in the photovoltaic product sector[9] - Total operating revenue for the first three quarters of 2025 was CNY 6,076,398,901.31, a decrease of 41.5% compared to CNY 10,346,604,131.14 in the same period of 2024[21] - Total operating costs for the first three quarters of 2025 were CNY 6,568,014,689.35, down 42.5% from CNY 11,434,187,255.83 in 2024[21] - The company has seen a significant reduction in operating costs by 45.43%, attributed to decreased sales in the photovoltaic sector[10] Cash Flow - The cash flow from operating activities for the year-to-date is CNY 1,749,106,478.58, an increase of 262.63% year-on-year[5] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 7,084,832,597.41, a decrease of 13.6% compared to CNY 8,203,445,609.04 in the same period of 2024[23] - The net cash flow from operating activities turned positive at CNY 1,749,106,478.58, compared to a negative CNY 1,075,489,435.54 in the previous year[23] - Cash outflow for purchasing goods and services was CNY 4,171,346,616.76, down 45.5% from CNY 7,665,757,419.38 in 2024[23] - The net cash flow from investing activities was negative at CNY -135,554,150.56, worsening from CNY -67,832,343.06 in the previous year[24] - Cash inflow from financing activities increased to CNY 10,063,871,127.35, up from CNY 9,746,780,566.89 in 2024[24] - The net cash flow from financing activities was negative at CNY -1,775,802,522.73, compared to CNY -105,175,343.47 in the same period last year[24] - The ending cash and cash equivalents balance decreased to CNY 341,088,401.26 from CNY 723,505,756.53 in 2024[24] Assets and Liabilities - The total assets at the end of the reporting period amount to CNY 25,496,915,262.81, a decrease of 8.06% from the previous year[6] - The total assets decreased from CNY 27,731,165,581.57 in 2024 to CNY 25,496,915,262.81 in 2025, a reduction of approximately 8.1%[18] - Total liabilities decreased from CNY 22,953,774,837.57 in 2024 to CNY 20,883,701,045.08 in 2025, a decline of about 9.0%[18] - The company's total equity decreased from CNY 4,777,390,744.00 in 2024 to CNY 4,613,214,217.73 in 2025, a drop of approximately 3.4%[18] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 1,873,771,378 shares[13] - The largest shareholder, Shuangliang Group Co., Ltd., holds 329,370,517 shares, accounting for 17.58% of total shares[13] - The second-largest shareholder, Shanghai Tongsheng Yongying Enterprise Management Center, holds 319,222,403 shares, representing 17.04%[13] Inventory and Investments - Total current assets as of September 30, 2025, were 10,332,572,260.24 RMB, down from 11,960,253,567.84 RMB at the end of 2024[16] - Inventory increased to 1,708,635,343.35 RMB from 1,551,762,408.03 RMB year-over-year[16] - Long-term equity investments were valued at 518,709,700.93 RMB, slightly down from 541,798,689.03 RMB[16] - The company reported a 104.84% decrease in investment income, primarily due to losses from joint ventures[10] Impairment Losses - Credit impairment losses decreased to 81.47 million RMB, primarily due to reduced bad debt provisions[11] - Asset impairment losses amounted to 75.19 million RMB, mainly due to a decrease in inventory write-down provisions[11] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 184,159,289.75, down 17.9% from CNY 224,517,328.31 in 2024[21] Other Income - The company reported a significant increase in other income, totaling CNY 77,656,676.01 in 2025, compared to CNY 339,875,537.68 in 2024[21]

湖南丽臣实业股份有限公司 2025 年第三季度报告 证券代码：001218 证券简称：丽臣实业 公告编号：2025-035 湖南丽臣实业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 湖南丽臣实业股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 1,269,551,303.31 | 41.97% | 3, ...

Financial Performance - The company's operating revenue for the third quarter was ¥199,582,874.65, a decrease of 7.01% compared to the same period last year[4] - The net profit attributable to shareholders was ¥4,960,493.27, down 74.70% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥3,101,606.30, a decline of 82.90%[4] - Total revenue for the current period was ¥489,918,608.22, a decrease of 12.9% compared to ¥562,850,543.01 in the previous period[25] - Net profit for the current period was a loss of ¥9,972,844.73, compared to a profit of ¥52,974,945.70 in the previous period, reflecting a significant decline in profitability[26] - Other comprehensive income after tax was a loss of ¥1,888,948.78 compared to a gain of ¥160,000.82 in the previous period, indicating a negative shift in comprehensive income[26] - The total comprehensive income for the period attributable to the parent company was -12,352,227.99 yuan, compared to 54,950,679.80 yuan in the previous period[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥870,780,927.58, representing a decrease of 8.08% from the end of the previous year[4] - Total assets decreased to ¥870,780,927.58 from ¥947,359,592.74, a decline of 8.1%[24] - Total liabilities decreased to ¥198,457,504.62 from ¥250,209,600.60, a reduction of 20.7%[24] - The company's cash and cash equivalents decreased to ¥157,278,589.18 from ¥281,103,026.60, representing a decline of 44%[20] - Accounts receivable decreased to ¥132,697,424.76 from ¥182,547,954.67, a reduction of 27.3%[22] - Inventory increased to ¥151,856,568.99 from ¥128,505,535.13, an increase of 18.1%[22] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥56,429,599.02, a significant decline of 453.58% compared to the same period last year[4] - The net cash flow from operating activities was -56,429,599.02 yuan, a decrease from 15,959,310.98 yuan in the previous period[30] - Cash inflow from operating activities totaled 614,046,470.41 yuan, up from 588,576,822.06 yuan year-over-year[30] - Cash outflow from operating activities increased to 670,476,069.43 yuan, compared to 572,617,511.08 yuan in the previous period[30] - The net cash flow from investing activities was -44,586,201.20 yuan, an improvement from -206,813,380.14 yuan in the previous period[30] - Cash and cash equivalents at the end of the period were 157,278,589.18 yuan, down from 308,991,491.68 yuan at the end of the previous period[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,106[10] - The largest shareholder, Wu Ning, holds 29.21% of the shares, amounting to 30,381,000 shares, with 18,300,000 shares pledged[11] - The company has reported a total of 10 major shareholders, with the top 10 holding significant stakes in the company[12] - The company has a significant shareholder, Jinhua Xianhe Investment Partnership, holding 7.8 million shares, representing a substantial portion of the total shares[12] Management and Governance - The company has restructured its board of directors and appointed new senior management personnel during the meetings held on July 11 and July 28, 2025[13] - The company has established a strong governance framework by electing independent directors and forming specialized committees within the board[13] - The company has revised its articles of association and governance systems to comply with updated regulations and improve operational standards[15] Investments and Projects - The company has completed the investment project in Vietnam with a total investment of RMB 61.42 million, achieving a progress rate of 100.66%[17] - The company has canceled the special account for the fundraising project related to the Vietnam investment, streamlining its fundraising management[17] - A new subsidiary, Yangu (Beijing) Robot Intelligent Technology Co., Ltd., was established on September 16, 2025, with a registered capital of RMB 80 million, in line with the company's strategic planning[18] - The company is focused on expanding its market presence through strategic investments and partnerships in the robotics sector[18] - The company has engaged in various technology development activities, including software and industrial robot manufacturing, as part of its new subsidiary's business scope[19] Expenses - The company experienced a significant increase in management expenses, which rose by 68.81% to ¥6,046.47 million due to various cost increases[9] - The company reported a significant increase in research and development expenses to ¥19,438,656.48 from ¥15,806,564.86, an increase of 23.5%[25]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥162,094,670.66, representing a 48.04% increase year-over-year[5] - Net profit attributable to shareholders was ¥35,776,253.29, up 60.87% compared to the same period last year[5] - The basic earnings per share increased to ¥0.4112, reflecting a growth of 58.16% year-over-year[5] - The company’s net profit after deducting non-recurring gains and losses was ¥32,142,005.14, a 75.66% increase year-over-year[5] - Total operating revenue for Q3 2025 reached CNY 445,397,399, an increase of 20.2% compared to CNY 370,383,832.16 in the same period last year[19] - Net profit for the period was CNY 102,307,486.10, representing a growth of 19.9% compared to CNY 85,295,719.69 in the previous year[20] - Total comprehensive income amounted to CNY 102,202,121.07, an increase from CNY 85,261,702.64 in the previous period, representing a growth of approximately 19.4%[21] - Basic and diluted earnings per share increased to CNY 1.1730 from CNY 0.98, reflecting a growth of about 19.7%[21] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥1,771,238,073.01, a 2.12% increase from the end of the previous year[5] - The company's total assets increased to CNY 1,771,238,073.01, up from CNY 1,734,474,410.50 at the end of the previous period[17] - Current assets totaled CNY 1,531,121,588.59, a slight increase from CNY 1,501,061,741.89 in the prior period[17] - The total liabilities rose to CNY 261,474,875.06, compared to CNY 242,464,785.65 in the previous year, reflecting a growth of 7.6%[17] - The equity attributable to shareholders of the parent company increased to CNY 1,509,829,719.73 from CNY 1,489,198,629.03, reflecting a solid financial position[17] Cash Flow - The cash flow from operating activities showed a decline of 21.84% year-to-date, totaling ¥41,021,114.71[5] - Cash flow from operating activities generated a net amount of CNY 41,021,114.71, down from CNY 52,482,244.30, indicating a decrease of approximately 21.5%[23] - The company reported a decrease in cash received from operating activities, totaling CNY 423,516,675.88, compared to CNY 411,150,874.24 in the previous period, showing a slight increase of about 3.3%[22] - Cash inflow from investment activities totaled CNY 2,327,606,178.39, compared to CNY 2,128,309,945.11 in the previous period, marking an increase of about 9.4%[23] - Cash outflow from investment activities rose significantly to CNY 2,498,407,715.04 from CNY 1,839,772,897.17, representing an increase of approximately 36%[23] - The net cash flow from investment activities was negative at CNY -170,801,536.65, contrasting with a positive CNY 288,537,047.94 in the previous period[23] - Cash and cash equivalents at the end of the period stood at CNY 487,370,704.56, up from CNY 434,596,755.23, reflecting an increase of about 12.1%[23] - The company’s net increase in cash and cash equivalents was CNY -208,759,146.41, a significant decline from CNY 280,558,441.08 in the previous period[23] Shareholder Information - Major shareholder Zhou Shaohua holds 47.77% of the shares, totaling 41,557,725.0 shares[12] - The company has a total of 63,307,181.00 restricted shares, with 2,542,163.00 shares released during the period[13] - The company has a significant portion of shares pledged, with Wu Xingming pledging 5,400,000.00 shares out of his total 9,295,975.00 shares[12] - The total number of preferred shareholders is not applicable, indicating no preferred shares issued[13] - The company has not identified any related party transactions among shareholders during this reporting period[12] Operational Insights - The company reported a significant increase in financial assets, with trading financial assets rising by 52.31% to ¥471,353,399.67[9] - The company experienced a 180.84% increase in prepayments, amounting to ¥6,187,847.84, primarily due to increased material payments[9] - The company reported a 53.70% increase in taxes and surcharges, totaling ¥4,541,559.77, due to a decrease in input tax credits[9] - Research and development expenses for the quarter were CNY 16,983,581.37, up from CNY 15,839,908.79, indicating a focus on innovation[20] - The company plans to maintain its focus on market expansion and new product development in the upcoming quarters[14] - The company has not disclosed any new mergers or acquisitions during this reporting period[14]

北京赛升药业股份有限公司 2025 年第三季度报告 证券代码：300485 证券简称：赛升药业 公告编号：2025-039 北京赛升药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 1 北京赛升药业股份有限公司 2025 年第三季度报告 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 111,825,972.85 | 3.50% | 308,627,146 ...

Financial Performance - The company's operating revenue for the third quarter was ¥271,810,512.33, a decrease of 25.56% compared to the same period last year[4] - The total profit for the quarter was -¥33,066,093.07, representing a decline of 67.43% year-on-year[4] - The net profit attributable to shareholders was -¥32,860,872.11, down 75.56% from the previous year[4] - The net profit after deducting non-recurring gains and losses was -¥41,288,969.01, a decrease of 53.50% compared to the same period last year[4] - The basic earnings per share for the quarter was -¥0.03, a reduction of 50.00% year-on-year[4] - Total operating revenue for the first three quarters of 2025 was CNY 897.28 million, a decrease of 27.2% compared to CNY 1,234.01 million in the same period of 2024[17] - The net profit for the first three quarters of 2025 was a loss of CNY 58.05 million, compared to a profit of CNY 14.79 million in the same period of 2024[18] - The total comprehensive income for the first three quarters of 2025 was a loss of CNY 58.05 million, compared to a gain of CNY 14.79 million in 2024[18] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.05, compared to CNY 0.01 in the same period of 2024[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,302,298,524.30, a decrease of 1.11% from the end of the previous year[6] - The company's current assets decreased to CNY 632,801,142.90 from CNY 731,590,823.23, representing a decline of approximately 13.5%[15] - The total liabilities of the company were CNY 1,476,660,474.08, slightly up from CNY 1,466,213,654.44, indicating a marginal increase of about 0.2%[16] - The company's short-term borrowings rose to CNY 358,716,619.05 from CNY 328,930,302.95, an increase of approximately 9.1%[16] - Total assets as of September 30, 2025, were CNY 3,090,323,290.45, down from CNY 3,215,704,231.43 at the end of 2024[21] - Total liabilities as of September 30, 2025, were CNY 1,348,732,867.54, a decrease from CNY 1,445,739,299.49 at the end of 2024[22] - The company’s total equity as of September 30, 2025, was CNY 1,741,590,422.91, down from CNY 1,769,964,931.94 at the end of 2024[22] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥81,262,129.11, a decline of 280.58% year-on-year[4] - Cash flow from operating activities showed a net outflow of CNY 81.26 million, worsening from a net outflow of CNY 21.35 million in the same period last year[19] - Cash flow from investing activities resulted in a net outflow of CNY 18.99 million, compared to a net outflow of CNY 57.79 million in 2024[20] - The net cash flow from operating activities for the first three quarters of 2025 was CNY 43,333,191.58, compared to a net outflow of CNY 48,735,549.86 in the first three quarters of 2024[26] - The net cash flow from financing activities for the first three quarters of 2025 was -CNY 24,397,401.33, an improvement from -CNY 84,590,424.55 in the first three quarters of 2024[26] - The company reported a net cash outflow of CNY 17,214,083.09 in cash and cash equivalents for the first three quarters of 2025, an improvement from -CNY 171,087,366.68 in the same period of 2024[26] Research and Development - Research and development expenses increased to CNY 66.43 million, up 16.5% from CNY 56.85 million in the previous year[17] - Research and development expenses for the first three quarters of 2025 were CNY 64,018,279.74, an increase from CNY 55,264,801.38 in the same period of 2024[24] Shareholder Information - There are no significant changes in the top ten shareholders or their shareholding structure reported[13] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[14] Other Financial Metrics - The decline in revenue and profits was primarily attributed to a decrease in product sales prices and operating margins[9] - The company reported non-recurring gains of ¥8,428,096.90 for the quarter, down from ¥62,062,046.22 year-to-date[8] - The company reported an increase in accounts receivable to CNY 293,377,461.08 as of September 30, 2025, compared to CNY 270,346,693.36 at the end of 2024[21] - Cash and cash equivalents dropped significantly from CNY 363,906,189.12 to CNY 191,452,119.56, a decrease of about 47.4%[15] - The cash and cash equivalents at the end of the period increased to CNY 175.91 million, up from CNY 143.61 million at the end of the same period last year[20] - The total cash and cash equivalents at the end of the first three quarters of 2025 was CNY 97,946,781.38, compared to CNY 33,821,153.52 at the end of the same period in 2024[26] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year[27]